(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

A roundup of global health news reveals rising challenges, including Brazil's bird flu outbreak, vaccine policy changes by ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

Indiana has a new name. With its growing field of precision medicine and life sciences, the state has secured the title of Radiopharmaceutical Capital of the World.

MIT professor, Dr. Leonard Guarente, conducts research into sirtuin genes and the power of a molecule called NAD ...

Community Health Centers Discovery Project, supported by Novartis Pharmaceuticals Corporation, to increase awareness about Lp(a).

BioCrossroads, a life sciences initiative, led the effort to secure the states designation as the Radiopharmaceutical Capital ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes ...

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, ...